Iron accumulation in tumor-associated macrophages marks an improved overall survival in patients with lung adenocarcinoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 08 2019
05 08 2019
Historique:
received:
13
11
2018
accepted:
08
07
2019
entrez:
7
8
2019
pubmed:
7
8
2019
medline:
24
10
2020
Statut:
epublish
Résumé
Iron-loaded tumor-associated macrophages (iTAMs) show a pro-inflammatory phenotype, hallmarked by anti-tumorigenic activity and an ability to attenuate tumor growth. Here we explored the relevance of these findings in lung cancer patients by investigating the impact of the iTAM content in the tumor microenvironment (TME) on patient survival. We analyzed 102 human non-small cell lung cancer (NSCLC) paraffin-embedded archival tissue samples for iron levels and macrophage numbers. Interestingly, patients with lung adenocarcinoma accumulating iron in the TME show higher numbers of M1-like pro-inflammatory TAMs and a survival advantage compared to iron-negative patients. By contrast, in patients with lung squamous cell carcinoma iron in the TME does not affect survival, suggesting a unique influence of iron on different histological subtypes of non-small cell lung cancer (NSCLC). We conclude that in lung adenocarcinoma iron may serve as a prognostic marker for patient survival and as a potential therapeutic target for anti-cancer therapy.
Identifiants
pubmed: 31383898
doi: 10.1038/s41598-019-47833-x
pii: 10.1038/s41598-019-47833-x
pmc: PMC6683135
doi:
Substances chimiques
Iron
E1UOL152H7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11326Références
Clin Cancer Res. 2003 Feb;9(2):729-37
pubmed: 12576442
Front Immunol. 2017 Nov 08;8:1479
pubmed: 29167669
Eur Respir J. 2007 Aug;30(2):286-92
pubmed: 17504792
J Pathol Transl Med. 2015 Jul;49(4):318-24
pubmed: 26081823
Eur Respir J. 2009 Jan;33(1):118-26
pubmed: 19118225
Cancer Cell. 2015 Apr 13;27(4):462-72
pubmed: 25858805
Oncotarget. 2016 Jun 7;7(23):34217-28
pubmed: 27144518
Nat Rev Cancer. 2013 May;13(5):342-55
pubmed: 23594855
Lancet. 2011 Nov 12;378(9804):1727-40
pubmed: 21565398
Cancer Sci. 2014 Jan;105(1):1-8
pubmed: 24168081
Int J Biochem Cell Biol. 2017 Jul;88:181-195
pubmed: 28495571
BMC Cancer. 2010 Mar 25;10:112
pubmed: 20338029
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692
Cancer Metastasis Rev. 2006 Sep;25(3):315-22
pubmed: 16967326
Mayo Clin Proc. 2008 Mar;83(3):355-67
pubmed: 18316005
Transl Lung Cancer Res. 2016 Jun;5(3):288-300
pubmed: 27413711
Am J Respir Crit Care Med. 2008 Dec 1;178(11):1130-8
pubmed: 18723436
EBioMedicine. 2017 Jun;20:230-239
pubmed: 28499927
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Annu Rev Immunol. 2009;27:451-83
pubmed: 19105661
Semin Cancer Biol. 2008 Oct;18(5):349-55
pubmed: 18467122
Blood. 2016 Jan 28;127(4):473-86
pubmed: 26675351
Cancer. 1995 Jul 1;76(1):20-5
pubmed: 8630872
Ann N Y Acad Sci. 2016 Mar;1368(1):149-61
pubmed: 26890363
Oncology. 1999;57(2):138-42
pubmed: 10461061
Med Oncol. 2011 Dec;28(4):1447-52
pubmed: 20676804
Sci Rep. 2015 Sep 24;5:14273
pubmed: 26399191
PLoS One. 2014 May 01;9(5):e96285
pubmed: 24789352
PLoS One. 2012;7(12):e50946
pubmed: 23284651
Nat Nanotechnol. 2016 Nov;11(11):986-994
pubmed: 27668795
Cancer Res. 2011 Nov 1;71(21):6728-37
pubmed: 21875943
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Cancer Res. 2016 Feb 1;76(3):513-6
pubmed: 26772756
Clin Cancer Res. 2009 Sep 15;15(18):5646-61
pubmed: 19755392